PRESS RELEASE - Biotage GB Limited Biotage unveils Isolera Spektra with full PDA Spectral Scanning

Biotage, a leading global supplier of solutions and technology for analytical and medicinal chemistry, introduced Isolera Spektra. Uppsala, Sweden, April 12, 2012 -- Biotage (STO: BIOT), a leading global supplier of solutions and technology for analytical and medicinal chemistry, introduced Isolera Spektra. The new Isolera Spektra expands the scope of application of Biotages marketleading Flash Chromatography product line by increasing efficiency with significant solvent and time saving capabilities as well as enabling purity assessment technology. The new full PDA spectral scanning capability with ?-All detection and baseline correction generates real-time PDA spectral data for eluting compounds. This provides compound detection at any wavelength, enabling chemists to see how pure their eluting compounds are in both real-time and post-purification. Post-purification spectral analysis can also be conducted in both two dimensional and three dimensional displays for improved visibility of impurities and eliminating the need for post-flash TLC purity testing. The new proprietary TLC-to-Step gradient feature (patent-pending) instantly converts TLC separation data into an efficient step gradient and suggests a sample load for up to six compounds. Chemists can target one or more compounds for isolation, dramatically reducing solvent requirements and purification time compared to linear gradients. Used in conjunction with Biotage SNAP Ultra cartridges with their 2-3X loading capacity and flow rate advantage, researchers can routinely achieve total processing times and ultra-low solvent consumption volumes which previously were not possible with other flash instruments. Isolera Spektra is a revolutionary enhancement in flash purification. It transforms 1dimensional flash purification into 3D purification systems that can target a specific compound for isolation and characterize collected fractions for purity and spectral properties says Bob Bickler, Senior Product Manager, Biotage. This technology can have a huge positive impact on the amount of time that researchers need to invest in compound purification as well as the solvents they consume. These system improvements combined with high efficiency columns will quickly pay for themselves in any lab. For further information visit http://www.biotage.com or call: In Europe: +46 18 56 57 10 In North America: (Toll Free) 1 800 446 4752 In Japan: +81 422 28 1233 Other areas, please call: +46 18 56 57 10.

-EndsFor further press information at Biotage please contact: James Churchill Marketing Communications Biotage GB Limited Distribution Way Dyffryn Business Park Ystrad Mynach Hengoed, Wales CF82 7TS United Kingdom Tel: +44 (0)1443 811 849 Mobile: +44(0)7875484778 E-Mail: james.churchill@biotage.com About Biotage Biotage offers solutions, knowledge and experience in the areas of analytical and medicinal chemistry. Customers include the worlds top pharmaceutical and biotechnology companies, as well as leading academic institutes. The company is headquartered in Uppsala, Sweden, with offices in China, Japan, the United Kingdom, the United States and a worldwide network of distributors. Biotage has 272 employees with sales of 428.9 MSEK in 2010. Biotage is listed on the NASDAQ OMX Nordic Stock Exchange. Website: http://www.biotage.com